Fellowship · Miami, FL
Sponsored by University of Miami/Jackson Health System
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
Hepatology (Baltimore, Md.) · 2023 · 2,087 citations · Stephen Caldwell
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
The New England journal of medicine · 2024 · 257 citations · Cynthia Levy
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
The New England journal of medicine · 2024 · 236 citations · Cynthia Levy
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.
Journal of hepatology · 2025 · 126 citations · Julio Gutierrez
Indomethacin with or without prophylactic pancreatic stent placement to prevent pancreatitis after ERCP: a randomised non-inferiority trial.
Lancet (London, England) · 2024 · 99 citations · Field Willingham
Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study.
Journal of hepatology · 2021 · 397 citations · Patricia Jones
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
The lancet. Gastroenterology & hepatology · 2026 · 28 citations · Cynthia Levy
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
Hepatology (Baltimore, Md.) · 2021 · 312 citations · Eugene Schiff